0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Reply to “Potential confounders in linking elevated S100A8/A9 to left ventricular dysfunction in septic shock patients”

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We would like to address the comments by Honoré et al. [1] referring to our recently published paper “Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis‑induced myocardial dysfunction” [2]. In their commentary, Honoré et al. highlighted the importance of renal replacement therapy (RRT) as a potential factor that might have impacted the measurement of plasma S100A8/A9 in our study. Since the molecular weight of the S100A8/A9 heterodimer (24 kDa) is lower than the cutoff value of the extracorporeal purification membrane (35–40 kDa), the use of RRT might partly remove S100A8/A9 from the circulation, leading to falsely low values of the protein in plasma. The authors of the comment argue that this might have led to erroneous conclusions regarding the positive relationship between elevated plasma S100A8/A9 and the development of sepsis-induced myocardial dysfunction (SIMD) demonstrated by our study [2]. The concern regarding the influence of RRT on biomarker values in the context of sepsis is not specific for S100A8/A9 and has previously been expressed by Honoré et al. in reference to other studies [3]. We agree that biomarker washout by RRT is an important factor that might impact both clinical studies and clinical practice, regardless of the initial pathology leading to renal failure. However, we would like to stress that in our study, S100A8/A9 was measured in plasma collected within 12 h from admission to the intensive care unit (ICU), as mentioned in the Methods section [2]. At this early time point, none of the sepsis patients included in the cohort had received RRT. Subsequently, the results of our study showing that plasma S100A8/A9 is elevated in severe sepsis patients with SIMD have not been impacted by the use of RRT and remain valid.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not

          Background The evolution of renal replacement therapy (RRT) techniques, and the increasing number of critically ill patients receiving extracorporeal therapies, has presented clinicians with a significant problem: if biomarkers are removed by RRT, can they still be considered reliable in their role of guiding diagnosis and treatment? The most commonly used RRT techniques in intensive care units (ICUs) can be classified into three categories: continuous renal replacement therapy (CRRT), intermittent hemodialysis (IHD), and hybrid techniques such as those performed with sorbent devices and plasma exchange (PE). These techniques remove substances from the plasma via convection, adsorption, or a combination of the two. Various factors determine the degree of removal, including molecular weight (MW) and charge, and the type of membrane and RRT technique used. IHD has a cut-off of 5 kDa in most cases and the risk of eliminating biomarkers is small. For CRRT, the cut-off value of the membranes is about 35 kDa, and as a result, filtration of a significant number of biomarkers may occur. New highly adsorptive membranes (HAMs), such as the acrylonitrile 69-surface treated (AN69-ST), are being used more frequently in ICUs [1]. This means that biomarkers with a MW above 35 kDa, while not removed by convection, may potentially be removed in a significant quantity by adsorption. With hybrid devices like CytoSorb, removal of hydrophobic substances with a MW up to 55 kDa occurs via selective binding [2]. PE has a cut-off of 1000 kDa and removes not only biomarkers but also a range of other substances including clotting factors and immunoglobulins. Clearance of a substance cannot always be predicted from MW and RRT membrane characteristics alone, highlighting the need for further studies to determine biomarker levels pre- and post-device for different CRRT techniques. For example, the relatively small MW (25 kDa) of high mobility group protein B1 (HMGB1), a damage-associated molecular pattern (DAMP) and marker of outcome, in theory does not prohibit its removal by convection. However, HMGB-1 is not eliminated by convection and is only effectively cleared through adsorption by HAMs like AN69-ST [3]. This occurs because it has a flat shape, and this prevents its passage through a CRRT membrane, despite its small MW. The degree of biomarkers removal by RRT, with the consequent effect on their serum levels, is essential information for clinicians (Fig. 1). Fig. 1 Biomarker molecular weight and removal by CRRT membranes Biomarkers eliminated by CRRT and sorbents C-reactive protein (CRP) is the most commonly used biomarker of inflammation. While often thought of as a pentamer with a MW of 125 kDa, CRP is predominantly present as a monomer (mCRP, MW 22–25 kDa) in the blood of septic patients and as such is removed by all forms of CRRT. Substantial amounts can also be eliminated via adsorption, by both conventional CRRT membranes and the CytoSorb device [4]. Procalcitonin (PCT), a biomarker used to detect (and exclude) the presence of infection and to monitor response to treatment, has a MW of 13.5 kDa and has been detected in the ultrafiltrate of patients undergoing CRRT [5]. Most of the PCT is eliminated by convection, but adsorption also contributes to elimination during the first hours of treatment [5]. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), biomarkers of cardiac dysfunction and outcome in sepsis, are also highly likely to be easily cleared by CRRT given their low MWs (3.5 kDa for BNP and 8.5 kDa for NT-proBNP) [6]. Mid-regional pro-adrenomedullin (MR-pro-ADM), a biomarker of sepsis severity and response to treatment, has a MW between 4 and 5.5 kDa, and its plasma concentration has been shown to decrease by 45–65% if a high-flux membrane is used [7]. Recently, presepsin has also been identified as a diagnostic biomarker of sepsis [8]. It has a MW of 13 kDa, which theoretically means that it could be subject to significant convective elimination. Given that RRT artificially decreases creatinine levels, a patient under RRT should be considered as having the full acute kidney injury in any score. Biomarkers not eliminated by CRRT or sorbents but needing further investigation Endocan is a diagnostic and prognostic biomarker for sepsis and acute respiratory distress syndrome [9]. CRRT with a membrane cut-off of 35 kDa is unlikely to remove endocan (MW 40 kDa), but removal may possibly occur by adsorption when HAMs are used [10]. Pentraxin 3 (PTX3), a marker of sepsis severity and a diagnostic marker for ventilator-associated pneumonia [11], has a MW of 35 kDa and thus, in theory, can be removed by CRRT. However, a recent study demonstrated little or no clearance or absorption by the filter during CVVH [12]. Heparin binding protein (HBP), a predictor of sepsis-induced organ dysfunction [13], has a MW of 37 kDa and as such should not be removed by convection. HBP has been detected in the effluent of patients undergoing CRRT, without a consistent decrease in plasma levels [14]. Studies are needed to investigate whether adsorption is possible. Osteopontin (OPN) is a predictor of outcome in critically ill patients [15]. A highly negatively charged protein with a MW of 32 kDa, osteopontin can theoretically be removed by CRRT, but at this time evidence is lacking. Table 1 summarizes all biomarkers described in this review with their MW, ability to be removed by convection and/or adsorption, and whether a study focusing on removal via RRT has been performed. Table 1 Biomarker molecular weight, potential removal by CRRT or sorbents, and summary of the available studies and the studies that need to be realized of levels in the context of RRT Biomarker Molecular weight (kDa) Elimination by CRRT Elimination by sorbents Existing studies Studies needed mCRP 20–25 + + + + PCT 14.5 + + + + BNP 3.5 + + + + NT-ProBNP 8.5 + + + + HMGB-1 25 + (adsorption only) + + – OPN – + – + Endocan 40 – + – + MR-pro-ADM 4–5.5 + – – + PTX3 35 – + + + Presepsin 13 + + + + HBP 37 – + – + kDa kilodalton, CRRT continuous renal replacement therapy, mCRP monomeric C-reactive protein, PCT procalcitonin, NT-ProBNP N-terminal pro-hormone of brain natriuretic peptide, OPN osteopontin, HMGB-1 high mobility group protein B1, MR-pro-ADM mid-regional pro-adrenomedullin, HBP heparin binding protein Conclusions It is likely that many sepsis biomarkers may be removed by convection, and therefore, their reliability as markers in patients undergoing CRRT is under question. Furthermore, the increasing use of HAMs makes the removal of many biomarkers even more likely. It is possible that some biomarkers may still have utility in the role of guiding diagnosis and treatment of critically ill patients on CRRT; however, further studies exploring biomarker elimination by CRRT are needed to confirm this. The development of new reference ranges for biomarkers in the setting of RRT would also be an interesting avenue of study. Beyond their utility as biomarkers, there are still many other questions to answer, such as whether removal of these, and other, substances by CRRT may result in benefit or harm.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction

            Background and Aims The triggering factors of sepsis-induced myocardial dysfunction (SIMD) are poorly understood and are not addressed by current treatments. S100A8/A9 is a pro-inflammatory alarmin abundantly secreted by activated neutrophils during infection and inflammation. We investigated the efficacy of S100A8/A9 blockade as a potential new treatment in SIMD. Methods The relationship between plasma S100A8/A9 and cardiac dysfunction was assessed in a cohort of 62 patients with severe sepsis admitted to the intensive care unit of Linköping University Hospital, Sweden. We used S100A8/A9 blockade with the small-molecule inhibitor ABR-238901 and S100A9 −/− mice for therapeutic and mechanistic studies on endotoxemia-induced cardiac dysfunction in mice. Results In sepsis patients, elevated plasma S100A8/A9 was associated with left-ventricular (LV) systolic dysfunction and increased SOFA score. In wild-type mice, 5 mg/kg of bacterial lipopolysaccharide (LPS) induced rapid plasma S100A8/A9 increase and acute LV dysfunction. Two ABR-238901 doses (30 mg/kg) administered intraperitoneally with a 6 h interval, starting directly after LPS or at a later time-point when LV dysfunction is fully established, efficiently prevented and reversed the phenotype, respectively. In contrast, dexamethasone did not improve cardiac function compared to PBS-treated endotoxemic controls. S100A8/A9 inhibition potently reduced systemic levels of inflammatory mediators, prevented upregulation of inflammatory genes and restored mitochondrial function in the myocardium. The S100A9 −/− mice were protected against LPS-induced LV dysfunction to an extent comparable with pharmacologic S100A8/A9 blockade. The ABR-238901 treatment did not induce an additional improvement of LV function in the S100A9 −/− mice, confirming target specificity. Conclusion Elevated S100A8/A9 is associated with the development of LV dysfunction in severe sepsis patients and in a mouse model of endotoxemia. Pharmacological blockade of S100A8/A9 with ABR-238901 has potent anti-inflammatory effects, mitigates myocardial dysfunction and might represent a novel therapeutic strategy for patients with severe sepsis. Graphical Abstract Supplementary Information The online version contains supplementary material available at 10.1186/s13054-023-04652-x.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Potential confounders in linking elevated S100A8/A9 to left ventricular dysfunction in septic shock patients

              Jakobsson et al. investigated the role of S100A8/A9, a pro-inflammatory alarmin, in sepsis-induced myocardial dysfunction (SIMD). They concluded that elevated S100A8/A9 is associated with the development of left ventricular (LV) dysfunction in severe sepsis patients [1]. Patients 18 years of age and older admitted to the intensive care unit (ICU) with septic shock (per Sepsis III) were included in this study [1]. Thirty-five out of sixty-two (56%) patients had LV dysfunction. Plasma S100A8/A9 was significantly higher in LV dysfunction patients (20.1 μg/mL vs. 7.4 μg/mL, P = 0.009). Nearly half of critically ill patients, especially with septic shock, develop acute kidney injury (AKI), and 20–25% require renal replacement therapy (RRT) within the first ICU week [2]. Considering S100A8 (10.8 kDa) and S100A9 (13.2 kDa) molecular weights, as well as the molecular weight of the S100A8/A9 heterodimer (24 kDa) [3], continuous RRT (CRRT)—which has a cut-off value of 35–40 kDa—might eliminate these molecules, impacting bio marker levels, and potentially leading to artificially decreased S100A8/A9 levels [4, 5]. The absence of CRRT/RRT in the criteria and its impact on each group is a potential major comfounding factor that could heavily influence results [4, 5]. In a clinical setting, this could lead to inaccurate prognosis and unadapted support. It is necessary that a sensitivity analysis should be done after the exclusion of CRRT/RRT patients to clarify the performance of these biomarkers when they are not artificially removed by an extracorporeal purification technique [5].
                Bookmark

                Author and article information

                Contributors
                Alexandru.Schiopu@med.lu.se
                Journal
                Crit Care
                Critical Care
                BioMed Central (London )
                1364-8535
                1466-609X
                2 January 2024
                2 January 2024
                2024
                : 28
                : 9
                Affiliations
                [1 ]Department of Translational Medicine, Lund University, ( https://ror.org/012a77v79) Lund, Sweden
                [2 ]Department of Anaesthesia and Intensive Care, Biomedical and Clinical Sciences, Linköping University, ( https://ror.org/05ynxx418) Linköping, Sweden
                [3 ]Cardiac Inflammation Research Group, Clinical Research Center, 91:12, Jan Waldenströms Gata 35, 21 428 Malmö, Sweden
                [4 ]Department of Internal Medicine, Skane University Hospital, ( https://ror.org/02z31g829) Lund, Sweden
                [5 ]GRID grid.418333.e, ISNI 0000 0004 1937 1389, Nicolae Simionescu Institute of Cellular Biology and Pathology, ; Bucharest, Romania
                Article
                4789
                10.1186/s13054-023-04789-9
                10762927
                fc080d89-4323-46c2-9e33-9d113f6cb511
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 20 December 2023
                : 22 December 2023
                Categories
                Matters Arising
                Custom metadata
                © BioMed Central Ltd., part of Springer Nature 2024

                Emergency medicine & Trauma
                Emergency medicine & Trauma

                Comments

                Comment on this article